Maegim한국어

바이오톡스텍

086040KOSDAQSector: Pharma & Biotech
₩2,060▲ 2.49%Market cap ₩32.9BAs of Jul 21, 2026 close · updated once daily
C
Grade C50.1 ptsTop 53% of 2,523 stocks
Financial strength
31.5
Growth momentum
52.2
Price attractiveness
69.9

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

31.5
How much debt does it carry relative to equity?
Debt-to-equity ratio
312.2%
✗ Below median · Top 94.9% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
56.9%
✗ Below median · Top 89.6% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
-10.2%
✗ Below median · Top 54.1% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
2.9%
✓ Above median · Top 35.2% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

52.2
How much did revenue grow in a year?
Revenue growth (YoY)
13.7%
✓ Above median · Top 33.1% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
8.0%
✓ Above median · Top 39.3% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
45.8%
✓ Above median · Top 22.5% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
-701.2%
✗ Below median · Top 96.5% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

69.9
Is the price expensive relative to earnings?
P/E (price-to-earnings)
28.3x
✓ Above median · Top 30.3% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.82x
✓ Above median · Top 29.9% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15